

IN THE CLAIMS:

Please cancel Claims 6 to 13 currently on file in the application and substitute the clean version of new Claims 14 to 20 as attached herewith.

REMARKS

In the Office Action, the Examiner states that Claims 6 to 13 are pending in the application and that claims 6 to 13 are rejected. By the present Amendment, Applicant amends the Specification, cancels Claims 6 to 13, and adds Claims 14 to 20.

In paragraph 1 of the Office Action, the Examiner states that the claim for priority is not yet complete. Applicant notes that the U.S. patent office acknowledged receipt of a copy of the priority document in the present case on November 1, 2001, and that the Patent Office stated that all 35 USC requirements were met on December 18, 2001 in a mailing dated January 7, 2002. Accordingly, Applicant believes that requirements to enter the national stage of U.S. prosecution with the claim for foreign priority have been met.

Also in paragraph 1 of the Office Action, the Examiner states that the first paragraph of the Specification fails to refer to the PCT parent application. Applicant attaches a new paragraph referring to the PCT parent application to this Amendment.

In paragraph 3 of the Action, the Examiner rejects Claims 6 to 13 under 35 USC 112, first paragraph, as non-enabling for a composition comprising any other biocompatible polymers than polyvinyl pyrrolidone and/or polyethylene oxide, or any other antioxidants than Trilon B. Applicant points out that the new Claims are directed to drugs comprising genetically engineered interferon